Sneak Preview: Vindication

Vindication! UroGen Shares Soar On Approval, It's Time to Cash Out ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  

Topline Trader #273: Vindication! UroGen Shares Soar On Approval, It's Time to Cash Out

Sneak Preview: Vindication Dear Reader, I wanted to give you a sneak preview of an email that went out yesterday to members of our premium biotech trading service Topline Trader. Check it out below... Vindication!  I'll be the first to admit that our UroGen trade has been a wild rollercoaster ride since we pulled the trigger back on January 24, 2025. From the highs of UroGen releasing strong data from its pivotal ENVISION trial that demonstrated an 18-month duration of response of 80.6%, to the lowest of the lows when the ADCOM meeting blindsided the company and voted against UGN-102.  Watching shares crash nearly 60% within a few days after that decision wasn't easy to stomach. However, I noted at the time that even though the risk surged higher, there was a huge upside if the FDA ultimately ruled in favor of UroGen.  In fact, we weren't the only ones that thought the stock was grossly undervalued, and to give UroGen a bit of credit, shares started rallying in the first week of June.  Then it happened.  Just as we had hoped, the FDA announced its approval of UGN-102 (now named Zusduri) on June 13, 2025.  The news sent UroGen shares surging higher. But it wasn't enough for us — we wanted more!  Today, our UroGen shares are soaring higher again, jumping nearly 20%. To put a little perspective on how explosive this move is, keep in mind that shares have climbed 312% since the fallout from that devastating ADCOM meeting!  Now our move is simple and sweet — we're pocketing our hard-fought gains and officially putting this catalyst trade in the win column.  Trading Action to Take: Sell UroGen Pharma (NASDAQ: URGN) Good Trading, Keith Kohl   If you are a member of Topline Trader, congrats!  If you are interested in joining, you can do so here. Stay safe out there, Jason Freiert CEO, Angel Investment Research If you no longer wish to receive updates from The Back office you may opt out here. The Back Office, Copyright © 2025, Angel Publishing, LLC., 3 E. Read Street, Baltimore, MD 21202. For customer service, please call 877-303-4529. All rights reserved. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. Angel Publishing and The Back Office does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. Unauthorized reproduction of this newsletter or its contents by Xerography, facsimile, or any other means is illegal and punishable by law.